Chinese Journal of Tissue Engineering Research ›› 2016, Vol. 20 ›› Issue (37): 5573-5579.doi: 10.3969/j.issn.2095-4344.2016.37.015

Previous Articles     Next Articles

Effects of tropomyosin 4 applied in spinal cord injuries via lentiviral vector recombination and the underlying mechanism: study protocol for a randomized controlled trial

Luo Su-yi1, Huang Wei2, Wang Jing3, Wang Xi-yun4, Li Jin-tao3   

  1. 1Department of Pathogenic Biology & Immunology, 3Institute for Neuroscience, 4Department of Anesthesiology Grade 2012, Kunming Medical University, Kunming 650500, Yunnan Province, China; 2Department of Neurology, the Third People’s Hospital of Yunnan Province, Kunming 650011, Yunnan Province, China
  • Online:2016-09-09 Published:2016-09-09
  • Contact: Li Jin-tao, M.D., Associate professor, Institute for Neuroscience, Kunming Medical University, Kunming 650500, Yunnan Province, China
  • About author:Luo Su-yi, Master, Teaching assistant, Department of Pathogenic Biology & Immunology, Kunming Medical University, Kunming 650500, Yunnan Province, China
  • Supported by:

    the Special Project for Applied Basic Research of Yunnan Provincial Science and Technology Department-Kunming Medical University

PDF

243

Abstract:

BACKGROUND: Tropomyosin 4 level has been found to be an increase in the spinal cord based on the 2-DE/MALDI-TOF/MS method. However, there is little report about the relationship between tropomyosin 4 and pathogenesis and progress of spinal cord injuries.
METHODS/DESIGN: Randomized controlled trial: rat models of complete spinal cord transection were made and expression levels of tropomyosin 4 at 3-28 days after modeling were determined by two-dimensional electrophoresis, animo acid serie analysis, quantitative PCR and western blot. Experiment for exporing the genetic mechanism: effects of tropomyosin 4 scilencing by lentivirus recomnination technology on the dendrite length of spinal cord neurons in vitro were observed, and its effects on the neurological function of rats after complete spinal cord transaction were assessed through Basso, Beattie, and Bresnahan scoring.
DISCUSSION: This study will be powered to provide a novel and effective treatment strategy for neurological function recovery after spinal cord transection based on the lentivirus recomnination carrying tropomyosin 4, as well as optimistic future for clinical gene treatment of complete spinal cord transaction through figuring out the underlying mechanism.
ETHICAL APPROVAL: This study was approved by the Ethics Committee of Kunming Medical University, China. The surgical operation and postoperative care of rats were in line with the rules of Chinese Experimental Animal Protection and Ethics Committee, and the guideline of the National Institutes of Health

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

Key words: Spinal Cord Injuries, Tropomyosin, Gene Knockout Techniques

CLC Number: